Advertisement
Australia markets close in 1 hour 45 minutes

  • ALL ORDS

    7,859.30
    -72.70 (-0.92%)
     

  • ASX 200

    7,597.00
    -67.10 (-0.88%)
     

  • AUD/USD

    0.6471
    -0.0008 (-0.13%)
     

  • OIL

    81.14
    -0.79 (-0.96%)
     

  • GOLD

    2,292.20
    -10.70 (-0.46%)
     

  • Bitcoin AUD

    93,108.51
    -5,037.74 (-5.13%)
     

  • CMC Crypto 200

    1,290.04
    -49.02 (-3.66%)
     

  • AUD/EUR

    0.6071
    +0.0005 (+0.09%)
     

  • AUD/NZD

    1.0988
    -0.0002 (-0.02%)
     

  • NZX 50

    11,865.83
    -91.67 (-0.77%)
     

  • NASDAQ

    17,440.69
    -342.02 (-1.92%)
     

  • FTSE

    8,144.13
    -2.90 (-0.04%)
     

  • Dow Jones

    37,815.92
    -570.17 (-1.49%)
     

  • DAX

    17,932.17
    -186.15 (-1.03%)
     

  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     

  • NIKKEI 225

    38,397.73
    -7.93 (-0.02%)
     

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Business Wire
·1-min read

GERMANTOWN, Md., March 06, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306655647/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com